Somewhat Favorable Media Coverage Somewhat Unlikely to Affect STAAR Surgical (STAA) Stock Price
News coverage about STAAR Surgical (NASDAQ:STAA) has been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. STAAR Surgical earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media stories about the medical instruments supplier an impact score of 45.9672094965263 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment’s rankings:
- STAAR Surgical Company (STAA) VP Sells $99,900.00 in Stock (americanbankingnews.com)
- Benchmark Co. Reiterates “Buy” Rating for STAAR Surgical Company (STAA) (americanbankingnews.com)
- Staar Surgical plans pivotal of Visian EVO ICL presbyopia optic for Q1 2018 (massdevice.com)
- STAAR Surgical Company (NASDAQ:STAA) Files An 8-K Regulation FD Disclosure (4-traders.com)
- Canaccord Genuity Boosts STAAR Surgical Company (STAA) Price Target to $20.00 (americanbankingnews.com)
A number of research analysts have issued reports on STAA shares. TheStreet upgraded STAAR Surgical from a “d+” rating to a “c” rating in a research report on Tuesday, August 15th. Benchmark Co. boosted their price target on STAAR Surgical from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, October 20th. Canaccord Genuity reiterated a “buy” rating and set a $15.00 price target on shares of STAAR Surgical in a research report on Sunday, October 8th. Zacks Investment Research lowered STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Friday, September 22nd. Finally, BidaskClub upgraded STAAR Surgical from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $17.67.
In other news, VP Keith Holliday sold 6,000 shares of the business’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $16.65, for a total value of $99,900.00. Following the sale, the vice president now owns 45,969 shares of the company’s stock, valued at approximately $765,383.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.60% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect STAAR Surgical (STAA) Stock Price” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/23/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-staar-surgical-staa-stock-price.html.
About STAAR Surgical
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
Receive News & Stock Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related stocks with our FREE daily email newsletter.